DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

ImmuneOnco Biopharmaceuticals has received approval from China’s National Medical Products Administration for a Phase II ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

The change comes as the company reaffirms its commitment to developing new off-the-shelf cellular immunotherapies.

Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Inflammation from lupus can cause a type of kidney disease called lupus nephritis. Learn more about how lupus affects the kidneys and lupus nephritis. For some people, lupus nephritis can lead to ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

Improvement in results on a noninvasive urinary biomarker panel at 3 months among patients with lupus nephritis predicted a clinical response at 1 year. A noninvasive urinary biomarker panel ...